## June 13, 2019

### CEPD Courses & Hungarian Track

<table>
<thead>
<tr>
<th>Time</th>
<th>CEPD 1</th>
<th>CEPD 2</th>
<th>CEPD 3</th>
<th>CEPD 4</th>
<th>CEPD 5</th>
<th>CEPD 6</th>
<th>CEPD 7</th>
<th>CEPD 8</th>
<th>CEPD 9</th>
<th>CEPD 10</th>
<th>CEPD 11</th>
<th>CEPD 12</th>
<th>CEPD 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45</td>
<td>Primary &amp; Secondary GN, vasculitis and autoimmune diseases</td>
<td>CKD</td>
<td>Hypertension, diabetes, CV diseases in CKD</td>
<td>Bone Mineral disorders in CKD</td>
<td>Genetic diseases and rare diseases</td>
<td>Basic &amp; translational Nephrology</td>
<td>Nephropathology course</td>
<td>Haemodialysis and vascular access</td>
<td>Renal transplantation</td>
<td>AKI</td>
<td>Peritoneal dialysis</td>
<td>Electrolytes and urolithiasis</td>
<td>ERA-EDTA Registry</td>
</tr>
<tr>
<td>12.25</td>
<td>Lunch break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>CEPD 8</td>
<td>CEPD 9</td>
<td>CEPD 10</td>
<td>CEPD 11</td>
<td>CEPD 12</td>
<td>CEPD 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### HUNGARIAN TRACK

**From the distant past to the sunny future**

1) **Can we talk about regional common fate in Nephrology?**
   - The European perspective (epidemiology)
   - The role of supranational-regional societies
   - Dialysis: from patient selection to privatization
   - Regional differences
   - Special issues of AKI and CKD in medium income regions

2) **From the molecule to social determinism. Challenges in Nephrology**
   - Molecular mechanisms/in vitro/in vivo models of disease
   - Translational medicine and real life
   - The kidney-gut axis
   - Choice of dialysis modality paediatrics vs adults
   - Transplantation
   - Psycho-nephrology

3) **The roots of adult diseases go back to childhood**
   - Are kidney diseases genetically encoded?
   - The role of prematurity in kidney diseases in children and adults
   - Hypertension management in children
   - Adolescent hypertension: transition from the child to the adult
   - Diabetes – the changing face of a disease
   - Progression of kidney disease in childhood

4) **The Hungarian perspective**
   - From Koranyi to WKD - Reestablishment of a European Centre
   - From RAS to renal tissue repair - visualization of physiology and pathophysiology
   - Non-traditional risk factors of kidney transplant recipients: pieces from a big Hungarian study
   - New challenges in kidney transplantation: machine perfusion

### WELCOME LECTURE

Diseases of emergence

**Rafael Yuste**, New York, NY, USA
June 14-15-16, 2019
56th ERA-EDTA Congress

Precision Nephrology
• What we know
• What we think we know
• What we need to know

PLENARY LECTURES

1) Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases
Sanjay Jain, Saint Louis, MO, USA

2) Single-cell transcriptomics in kidney disease
Katlin Susztak, Philadelphia, PA, USA

3) The pre-dialysis to renal replacement therapy transition
Csaba P. Kovesdy, Memphis, TN, USA

MINI LECTURES

• Renal and intestinal oxalate transport, inflammation and CKD
• Uric acid or potassium transporters
• Interallelic interactions of podocin
• Personalised diagnosis and CKD prediction in genetic tubular disorders
• Whole-exome sequencing in adults with CKD
• New therapies in the Henoch-Schönlein syndrome
• Role of complement in the pathogenesis of IgA nephropathy
• PCSK9 in kidney disease
• From human embryonic nephron stem cells to mature kidney tissue and regeneration
• Regenerative medicine
• Calciphylaxis
• The Swedish Health databases and kidney research
• When should a nephrologist take over - stage 3b or 4 - current perspective
• May we answer the question: “Doctor: how long may I live in dialysis”?
• Is there room to improve dialysis stability? Should we change time, dialysis modality, dialysate solute concentrations, dialysate temperature, all of them or none of it?
• How to measure residual renal function
• New approaches to enhance removal, particularly of protein bound solutes

SYMPOSIA

SPECIAL SYMPOSIA

ERA-EDTA Registry
- Administrative databases: potential and challenges
- Insights from Equal

Late Breaking Clinical Trials

ASN Highlights

Nephrology Pearls (special closing session)

Track 1
FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

Phosphate and FGF23
- FGF23 signalling in the kidney
- Regulation of FGF23
- Phosphate toxicity in the kidney
Track 2
HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

Redefining the ontology of kidney diseases using genomic analysis
- Genetic landscape of hereditary amyloidosis
- What’s up in hereditary tubulo-interstitial nephritis?
- Adult-onset ESRD of unknown aetiology: when should we think genetics?

Novel therapies in hereditary kidney diseases
- New therapeutic targets in Alport syndrome
- Targeted therapies in ADPKD: what will be in the pipeline in 2020?
- Therapeutic management of cystinuria: today and tomorrow

Paediatric Nephrology
- Childhood nephrotic syndrome: lessons from the PODONET registry
- Evidence based treatment of minimal change nephrotic syndrome: lessons from the PREDNOS trials
- Novel therapies for childhood minimal change nephrotic syndrome
- Blood pressure in children

Pregnancy
- AKI during pregnancy: no longer an issue?
- Lupus nephritis and pregnancy: concerns and management
- Preventing preeclampsia

Track 3
GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

The many faces of monoclonal gammopathy of undetermined significance
- MGRS classification: bringing order to the nomenclature chaos
- MGRS diagnosis: establishing causality is the hardest job
- MGRS treatment: should we follow the haematologist or take the lead?

Molecular mechanisms of kidney atrophy and fibrosis
- The cannabinoid system and CKD progression
- Does less fibrosis improve renal function? Insights from collagen I-deficiency
- Pathology and mechanisms of interstitial granuloma formation

AnCA-associated vasculitis
- Extrarenal involvement in AAV and its impact on the outcome of patients
- ANCA-associated vasculitis in the elderly and very elderly
- Should the anti-PR3 and anti-MPO patients be treated in a different way?

Lupus nephritis
- Histologic classification of lupus nephritis - is there already a time for change?
- Pathogenesis of SLE and systemic lupus nephritis - what is new?
- Biologic therapy in lupus nephritis - where are we now?

Primary glomerulonephritides
- Anti-THSD7A-positive disease, outcome and treatment
- Spontaneous remission in membranous nephropathy - how long should we wait?
- Serology-based algorithm of the treatment of membranous nephropathy
- What is the optimal approach to the treatment of IgA nephropathy in 2019?

Track 4
CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

The many facets of hypoxia in CKD
- Hypoxia and CKD progression
- Sleep disordered breathing: a pervasive problem in CKD
- Intradialysis hypoxia

Neuroinflammation and CKD
- The gut-brain axis, b2microglobulin and neuroinflammation: a re-interpretation of an old story?
- Anti-inflammatory role of the parasympathetic system in CKD
- Neuroinflammation and hypertension

The role of diet in the prevention of CKD progression: food for thought
- Kidney disease and the westernisation and industrialisation of food
- Dietary protein restriction: PRO
- Dietary protein restriction: AGAINST
- Sodium as a regulator of immunity

The gut-kidney-cardiovascular axis
- Gut microbiota and microbial metabolism in CKD across stages of diseases
- Gut dysbiosis and thrombosis
- Gut dysbiosis and vascular calcification
The paradox of estimated GFR in the era of precision medicine
- Overview of the error of creatinine and cystatin-c-based formulas in clinical practice
- Measured GFR in clinical practice, the Swedish experience
- Which method to measure GFR and in which clinical conditions?
- MRI approaches to assess kidney injury and function

New insights in molecular mechanism of cardiovascular diseases in CKD
- Oxidative stress on myocardial function in CKD
- Post-translational lipoprotein modification in uraemia
- Atherosclerosis, cardiac remodelling and CKD

Track 5 END-STAGE RENAL DISEASE, HAEMODIALYSIS
Haemodialysis. From incremental approaches to frequent treatments
- The concept of incremental dialysis
- Clinical experiences with incremental haemodialysis schedules
- Quality of life and haemodialysis frequency

Controversy: does haemodiafiltration improve patient outcomes and survival?
- No
- Yes
- Increasing convection: what happens to the different uraemic toxins when increasing convection in post-dilutional HDF?

Start dialysis? Stop dialysis? - Challenging conversations
- Dialysis or conservative care?
- Is this the time to consider dialysis withdrawal?
- Different conversations for different ethnic groups?

Delivering good quality dialysis - what should we measure?
- Small solute clearance: what are the pitfalls?
- Patient-reported outcomes: are these fit for purpose?
- Towards a multidimensional measure of dialysis adequacy?

The hidden risks of haemodialysis
- Silent ischemia during haemodialysis
- Haemodynamic instability and ischemic brain injury
- Tolerability of extracorporeal treatments in 2019

CKD-MBD patterns and therapeutic approaches: update 2019
- Klotho, a new player coming to age
- New insights in pathogenesis and treatment of vascular calcification
- Osteoporosis in CKD, a diagnostic and therapeutic challenge on the move

Track 6 HOME THERAPIES, PERITONEAL DIALYSIS
Optimising peritoneal dialysis prescription
- Why testing peritoneal membrane characteristics?
- Biomarkers to guide personalised interventions in peritoneal dialysis
- Individualising prescription for residual renal function

Home haemodialysis: on the move
- Reducing the costs of end stage renal disease while delivering quality health care: are home therapies the answer?
- Striving to achieve an integrated home dialysis system
- Vascular access in HHD: the Achilles tendon?

Frail elderly: management best at home
- Integrating geriatric assessment into routine dialysis care
- Outcomes on assisted PD
- Integrating with community geriatric services

Track 7 TRANSPLANTATION AND IMMUNOLOGY
Overcoming age with frailty evaluation in the kidney transplant recipient
- Is frailty evaluation a precise evaluation of the patient with chronic disease?
- The best frailty evaluation before kidney transplantation
- Outcomes of frail patients after kidney transplantation

Precision medicine for the sensitised transplant recipient. The TTT
- Tailoring a transplant route for the sensitised patient on dialysis
- Treating the patient while listed
- Taking care: balancing immunosuppression avoiding weapons of mass destruction

Basic immunology and pathology
- Necroinflammation in kidney transplantation
- Polyoma nephropathy
- Banff update
Improving the organ donor pool
- controlled Cardiac Donor Death program in Spain: one vision for the future
- Kidney protection in living donors
- Compatibility barriers/Increasing the pool of marginal donors

**Track 8**
**HYPERTENSION, DIABETES, VASCULAR DISEASES**

Improving outcomes in DKD
- Renal inflammation: its pathogenetic role in diabetic kidney disease
- Basic science: SGLT2 inhibitors in the prevention of renal fibrosis
- Update on SGLT2i in CKD
- GLP-1 receptor agonists in DKD: mechanisms and outcomes

Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?
- Salt and hypertension: a bacterial affair
- Tissue sodium storage in end stage kidney disease
- Gender and renal salt handling
- Renal potassium sensing and control of sodium balance

Cardiovascular disease in CKD: risk factors and remedies
- Why is the risk of stroke so high in CKD and in dialysis patients?
- Clinical trials and research priorities in dialysis patients
- Modifiable risk factors for cardiovascular disease in CKD: a hierarchical approach

Digging the aetiology of hypertension
- Biological insights from GWAS
- Why is CKD not considered a more frequent cause of hypertension?
- Insights from adverse effects of drugs

Blood pressure targets
- Optimal BP target for renoprotection in CKD patients is <140/90
- Optimal BP target for renoprotection in CKD patients is <130/80
- Managing resistant hypertension

**Track 9**
**ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY**

AKI: current problems in clinical practice
- To fill or not to fill: what is the evidence
- Heart failure and AKI
- Genetic variability and AKI
- Vascular surgery

Renal Replacement Therapy in the Intensive Care Unit
- Modality and dose: where do we stand?
- When to start dialysis: the final answer?
- The intertwined relation between CKD and AKI: pitfalls and cobblestones